<DOC>
	<DOC>NCT00863681</DOC>
	<brief_summary>Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.</brief_summary>
	<brief_title>BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1 Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as related to BAY632521 are not allowed to participate in the extension trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>Stimulator</keyword>
</DOC>